Press Releases

Date	Title
7/7/20	Vir Biotechnology Announces Pricing of Public Offering of Common Stock
7/6/20	Vir Biotechnology Announces Proposed Public Offering of Common Stock
5/29/20	Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment
5/27/20	Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
5/18/20	Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature
5/12/20	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
5/8/20	Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
5/7/20	Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference
5/4/20	Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
4/28/20	Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020

Vir - Investor Relations Menu